Canopy Growth Corp is a cannabis and hemp company built around medical cannabis brands, vaporizers, and a portfolio of U.S. cannabis investments held through Canopy USA. Its continuing operations are centered on Canadian cannabis, international medical cannabis, and the Storz & Bickel vaporizer business, while some legacy consumer wellness assets have been divested. The company sells branded flower, oils, extracts, and medically approved vaporizers, with a strong emphasis on regulated medical channels in Canada, Australia, and Europe. Canopy has also restructured its U.S. exposure to deconsolidate Canopy USA for Nasdaq compliance, while retaining economic interests in assets such as Acreage, Wana, Jetty, and TerrAscend through Canopy USA structures. The business remains in a turnaround and restructuring phase, with management focused on narrowing operations, preserving listing compliance, and improving execution in its core cannabis and device businesses.
−50,1 %
24,5 %
−92,4 %
+5,8 %
3.34
2.64
| % | |
|---|---|
| Canadian Cannabis | 45% Medical cannabis products sold in Canada, including flower, oils, and extracts. |
| International Markets Cannabis | 30% Medical cannabis and hemp products sold in Australia, Europe, and other regulated markets under Spectrum Therapeutics and Canopy Medical. |
| Storz & Bickel | 20% Medically approved vaporizers and related accessories sold globally. |
| Other and Ancillary | 5% Non-cannabis extraction activities and other ancillary revenue streams. |
Canopy Growth primarily serves medical cannabis patients and healthcare-oriented buyers who need regulated flower,...
Buy branded cannabis flower, oils, and extracts for therapeutic use in the Canadian medical market.
Licensed distributors, pharmacies, and medical buyers in Australia and Europe that purchase regulated cannabis products.
Buy Storz & Bickel vaporizers and accessories for inhalation of cannabis or related products.
Buy non-cannabis extraction or related ancillary offerings where available, typically as a smaller part of the business.
Canopy Growth’s core operating footprint is Canada, where it employs the majority of its workforce and where its...
Canopy Growth’s strategy is to concentrate on regulated cannabis and device businesses where it can sell branded...
International regulated markets offer a clearer path to branded cannabis growth than the fragmented U.S. market.
The company has restructured U.S. holdings to avoid direct consolidation of federally sensitive cannabis assets.
A narrower operating footprint should improve execution in production, distribution, and sales enablement.
Canopy USA provides economic exposure to U.S. assets without direct consolidation on Canopy Growth’s balance sheet.
Canopy Growth faces substantial regulatory and execution risk because cannabis remains a heavily controlled industry...
The company had to deconsolidate Canopy USA to align with Nasdaq’s position on federally illegal cannabis activities.
Management states it may not achieve or maintain profitability and may continue to incur losses.
Banks, suppliers, customers, and partners may be uncertain about the company’s U.S. strategy and legal interpretation.
Future revenue depends on new cannabis products and maintaining consumer brand recognition.
Publicized health concerns around vapes and vaporizer devices can affect demand and regulatory scrutiny.
CBDY · Medicinal Chemicals & Botanical Products
CPMD · Pharmaceutical Preparations
TCRG · Medicinal Chemicals & Botanical Products
TSNDF · Agricultural Production-Crops
GNLN · Wholesale-Durable Goods, NEC
Agricultural Production-Crops
Cannabist Co Holdings Inc., formerly Columbia Care, is a U.S.
: 28/04/2026